Invasive Candidiasis Therapeutics
1. Eraxis patent expiration
Treatment: Treatment of fungal infections
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5965525 | VICURON HOLDINGS | Cyclic peptide antifungal agents |
Feb, 2020
(5 years ago) | |
| US7709444 | VICURON HOLDINGS | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
Apr, 2021
(4 years ago) | |
| US6960564 | VICURON HOLDINGS | Echinocandin pharmaceutical formulations containing micelle-forming surfactants |
Apr, 2021
(4 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 22, 2023 |
Drugs and Companies using ANIDULAFUNGIN ingredient
Market Authorisation Date: 17 February, 2006
Dosage: POWDER
More Information on Dosage
ERAXIS family patents
2. Rezzayo patent expiration
Treatment: Treatment of candidemia and invasive candidiasis with rezafungin by intravenous administration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10702573 | MUNDIPHARMA | Dosing regimens for echinocandin class compounds |
Mar, 2033
(7 years from now) | |
| US9526835 | MUNDIPHARMA | Dosing regimens for echinocandin class compounds |
Mar, 2033
(7 years from now) | |
| US8722619 | MUNDIPHARMA | Antifungal agents and uses thereof |
Mar, 2032
(6 years from now) | |
| US11197909 | MUNDIPHARMA | Compositions and methods for the treatment of fungal infections |
Jul, 2038
(12 years from now) | |
| US11654196 | MUNDIPHARMA | Dosing regimens for echinocandin class compounds |
Mar, 2032
(6 years from now) | |
| US11819533 | MUNDIPHARMA | Compositions and methods for the treatment of fungal infections |
Jul, 2038
(12 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11712459 | MUNDIPHARMA | Dosing regimens for treatment of fungal infections |
Mar, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 22, 2028 |
| Orphan Drug Exclusivity(ODE-426) | Mar 22, 2030 |
| Generating Antibiotic Incentives Now(GAIN) | Mar 22, 2033 |
Drugs and Companies using REZAFUNGIN ACETATE ingredient
NCE-1 date: 22 March, 2032
Market Authorisation Date: 22 March, 2023
Dosage: POWDER
More Information on Dosage
REZZAYO family patents